Stocksigma LogoStocksigma Logo

Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations

The USFDA concluded a cGMP inspection at Granules India's Gagillapur finished dosage facility on 30th Oct'26, issuing a Form 483 with 11 observations

Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations

Granules India Ltd 路 Press Release 路 31 Oct 2026, 4:17 am

Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations The USFDA concluded a cGMP inspection at Granules India's Gagillapur finished dosage facility on 30th Oct'26, issuing a Form 483 with 11 observations. This marked the site's first inspection since receiving a Warning Letter on 26th Feb'25. Observations relate to investigations, change control, equipment qualification, visual inspection, and documentation practices, with zero issues concerning data integrity or cross-contamination. Current manufacturing and distribution remain unaffected, and the company plans to submit its comprehensive response within the mandated 15 business days.

Original exchange filing (PDF)

More announcements from Granules India Ltd

All Granules India Ltd announcements